Live tape
Top 8, mentions 7d29,951NVDA14,531 mentions▲ +0.04ANT4,153 mentions▲ +0.07GOOGL2,924 mentions▲ +0.04SPY2,246 mentions▲ +0.05QQQ1,802 mentions▲ +0.04SPCX1,745 mentions▲ +0.08AMD1,365 mentions▲ +0.06AAPL1,185 mentions▲ +0.04

Equity · Healthcare

AMLX

NASDAQ

Amylyx Pharmaceuticals (AMLX)

26.03 USD −0.53% vs prior close Nov 20, 2026
Amylyx Pharmaceuticals, Inc. price graph
64 sessions
40 25 24 Aug 20 Nov

The line runs 38 USD on 24 August through 26.03 USD on 20 November, on a scale from 25 to 40. Days the market did not trade hold the previous close, flat.

Market cap
3.3B USD
Revenue, year to Dec 2025
0 USD
EPS, diluted, year to Dec 2025
−1.53 USD
52-week range
11 USD – 39.67 USD
Avg volume
86.4K

as of Nov 20, 2026

Have Amylyx Pharmaceuticals (AMLX) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Amylyx Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 21 May 2026.

Form 4, 90 days to 22 Nov 2026, newest reported trade 10 Nov 2026

0buys
10sells
$10.95Mnet sold
3other filings
Have Amylyx Pharmaceuticals (AMLX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Nov 2026FRATES JAMES MChief Financial OfficerSell20,000611K USD
09 Nov 2026Cohen Joshua BCo-Chief Executive OfficerSell100,0003.0M USD
09 Nov 2026Klee Justin B.Co-Chief Executive OfficerSell100,0003.0M USD
09 Nov 2026FRATES JAMES MChief Financial OfficerSell20,000597K USD
05 Oct 2026MILNE GEORGE M JRDirectorSell30,000831K USD
10 Sep 2026Bedrosian Camille LChief Medical OfficerSell10,028325K USD
10 Sep 2026FRATES JAMES MChief Financial OfficerSell10,810350K USD
10 Sep 2026Mazzariello GinaChief Legal OfficerSell9,536310K USD
10 Sep 2026Cohen Joshua BCo-Chief Executive OfficerSell30,464981K USD
10 Sep 2026Klee Justin B.Co-Chief Executive OfficerSell30,464980K USD
Sold10 open-market sales361,302$10.95M
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Amylyx Pharmaceuticals (AMLX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Nov 2026FRATES JAMES MChief Financial OfficerOption exercise20,000138K USD
09 Nov 2026FRATES JAMES MChief Financial OfficerOption exercise20,000138K USD
31 Aug 2026Firestone KarenDirectorOption exercise50,000170K USD

Which funds hold Amylyx Pharmaceuticals (AMLX)?

8 of the 45 institutional funds we track reported a Amylyx Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 79.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Amylyx Pharmaceuticals (AMLX)?
FundPositionSharesValueShares q/q
Two Sigma InvestmentsHeld (±25%)669,83819.5M USD+12.9%
D. E. Shaw & Co.Added516,17015.0M USD+196.2%
Citadel AdvisorsAdded488,57114.2M USD+173.4%
Point72 Asset ManagementNew position388,69911.3M USD
Marshall WaceNew position377,02611.0M USD
Millennium ManagementNew position191,6895.6M USD
Renaissance TechnologiesNew position72,9352.1M USD
AQR Capital ManagementAdded35,2811.0M USD+69.5%
Balyasny Asset ManagementExited
Tudor Investment CorpExited

Have members of Congress traded Amylyx Pharmaceuticals (AMLX)?

The most recent congressional trade disclosed in Amylyx Pharmaceuticals is a purchase by Sara Jacobs (house, CA), dated 12 Oct 2022.

STOCK Act disclosures

Have members of Congress traded Amylyx Pharmaceuticals (AMLX)?
TradedMemberTypeAmountFiled after
12 Oct 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD35 days

What has been filed or recorded for Amylyx Pharmaceuticals (AMLX)?

The filings we hold for Amylyx Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 22 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Amylyx Pharmaceuticals (AMLX)?
And
22 Oct 2026Fails to deliverShares failed to deliver200,000 shares5.8M USD notional · 0.156% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.38 USD
30 Sep 2026FinancialsTotal assets786.8M USDat period end
30 Sep 2026FinancialsTotal equity753.7M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.39 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.37 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.53 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−144.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.53 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.37 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.46 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.42 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −4.43 USD

What do people ask about Amylyx Pharmaceuticals (AMLX)?

From live data
What did Amylyx Pharmaceuticals shares close at?26.03

Amylyx Pharmaceuticals closed at 26.03 USD on 20 Nov 2026, down 0.53% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Amylyx Pharmaceuticals’ market cap?3.3B

Amylyx Pharmaceuticals is worth 3.3B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Amylyx Pharmaceuticals’ revenue?0

Amylyx Pharmaceuticals reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Amylyx Pharmaceuticals insiders bought or sold shares recently?10 sales

In the 90 days to 22 Nov 2026, Amylyx Pharmaceuticals insiders reported 10 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 21 May 2026. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Amylyx Pharmaceuticals?8 of 45

8 of the 45 funds we track reported a Amylyx Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, D. E. Shaw & Co. and Citadel Advisors. See Funds

Have members of Congress traded Amylyx Pharmaceuticals?1 trade

Yes. 1 trade in Amylyx Pharmaceuticals appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Oct 2022, filed 16 Nov 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Amylyx Pharmaceuticals last report earnings?−0.38

Amylyx Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.38 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings
  11. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words